Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Development of a model to demonstrate the impact of NICE cost-effectiveness assessment on health utility for targeted medicines

Tools
- Tools
+ Tools

Gallacher, Daniel C., Stallard, Nigel, Kimani, Peter K., Gökalp, Elvan and Branke, Juergen (2022) Development of a model to demonstrate the impact of NICE cost-effectiveness assessment on health utility for targeted medicines. Health Economics, 31 (2). pp. 417-430. doi:10.1002/hec.4459

[img]
Preview
PDF
WRAP-development-model-demonstrate-the-impact-NICE-cost-effectiveness-assessment-health-utility-targeted-medicines-2021.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (916Kb) | Preview
[img] PDF
WRAP-development-model-demonstrate-the-impact-NICE-cost-effectiveness-assessment-health-utility-targeted-medicines-2021.pdf - Accepted Version
Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer.

Download (924Kb)
Official URL: https://doi.org/10.1002/hec.4459

Request Changes to record.

Abstract

Advances in medical technology have led to a better understanding of heterogeneity of diseases and patients, and to the development of targeted medicines. This development is beneficial to society but can come at an increased cost to pharmaceutical manufacturers due to the costs associated with developing and manufacturing a diagnostic test. For such medicines, the conventional pricing structure, where a therapy is approved if it is deemed cost-effective, may not appropriately incentivise targeted drug development. We model the decision-making processes for both the healthcare provider and the pharmaceutical manufacturer, capturing their main priorities, and populate it with information from a recent appraisal by the National Institute of Health and Care Excellence. Healthcare providers prefer a stratified drug to be developed for a subgroup of the population when the drug is on average effective in the subgroup but with a detrimental effect in the complement. Whilst pharmaceutical manufacturers’ preferences are similar, regions of disagreement exist. We show how preferences can be aligned by either penalising the development of a non-stratified drug or rewarding the development of a stratified drug. The cost and position of alignment depends on the true value of health to the healthcare provider, among other parameters.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
R Medicine > RA Public aspects of medicine
Divisions: Faculty of Social Sciences > Warwick Business School > Operational Research & Management Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET)
Faculty of Social Sciences > Warwick Business School
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Medical economics, Medical care, Cost of, Medical informatics, Medical technology -- Cost effectiveness, Medical innovations -- Cost effectiveness
Journal or Publication Title: Health Economics
Publisher: John Wiley & Sons Ltd.
ISSN: 1057-9230
Official Date: February 2022
Dates:
DateEvent
February 2022Published
25 November 2021Available
9 November 2021Accepted
Volume: 31
Number: 2
Page Range: pp. 417-430
DOI: 10.1002/hec.4459
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
EP/P006485/1[EPSRC] Engineering and Physical Sciences Research Councilhttp://dx.doi.org/10.13039/501100000266
Related URLs:
  • Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us